GILEAD SCIENCES CMV TRIAL DATA MAKE FOR BALMY VIEW BY THE STREET IN JANUARY
Executive Summary
Gilead Sciences started off the new year by gaining 3-1/2 points (36.8%) in January as the Foster City, Calif.-based company announced positive study results for its lead product, Vistide (cidofovir), for treatment of cytomegalovirus retinitis in AIDS patients